JW Pharmaceutical Attends 'BioUSA'... Pursues Technology Partnership for New Drug Candidates

[Asia Economy Reporter Lee Gwan-joo] JW Pharmaceutical announced on the 7th that it will participate in the '2022 BIO International Convention (BIO USA)' held in San Diego, USA, for four days starting from the 13th of this month, conducting technology partnership consultations with overseas pharmaceutical companies through one-on-one meetings.

JW Pharmaceutical plans to discuss technology partnership projects for its self-developed innovative drug candidates through the BIO One-on-One Partnering System provided by BIO USA and confidential individual meetings.

First, it will promote the technology export of the gout drug candidate 'URC102' targeting the global market excluding China. URC102 is a uric acid excretion promoter that inhibits URAT1 (uric acid transporter-1), and is a new drug candidate for gout disease caused by hyperuricemia. It demonstrated high safety and excellent efficacy in the domestic Phase 2b clinical trial completed in March last year, and is currently conducting clinical trials to expand the target to patients with renal impairment.

It will also pursue technology partnerships for the STAT3-targeting anticancer agent 'JW2286'. JW2286 has a mechanism that inhibits STAT3 and is indicated for solid tumors including triple-negative breast cancer. It is currently undergoing non-clinical trials with the goal of starting clinical trials next year. STAT3 is a protein that promotes the expression of various genes within cells. When STAT3 is abnormally activated, it induces cancer cell growth, proliferation, metastasis, and drug resistance; however, no new drugs targeting STAT3 have been developed to date.

Additionally, the latest research status and development strategy for the hair loss treatment 'JW0061', which activates the Wnt signaling pathway to differentiate and promote cells involved in hair follicle stem cells and hair formation, will be explained.

A JW Pharmaceutical official said, “We will conduct various technology partnership discussions related to patient-tailored innovative drug candidates focusing on oncology, immunology, and regenerative medicine,” and added, “We expect significant interest from global pharmaceutical companies and investors in JW’s research and development capabilities.”

This content was produced with the assistance of AI translation services.